サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1585128

アジア太平洋のコンパニオン診断市場：技術別、用途別、エンドユーザー別、国別 - 分析と予測（2023年～2033年）

Asia-Pacific Companion Diagnostics Market: Focus on Application, End User, Technology, and Country - Analysis and Forecast, 2023-2033

出版日
発行
BIS Research
ページ情報
英文 73 Pages
納期
1～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.50円
アジア太平洋のコンパニオン診断市場：技術別、用途別、エンドユーザー別、国別 - 分析と予測（2023年～2033年）
出版日: 2024年11月08日
発行: BIS Research
ページ情報: 英文 73 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋のコンパニオン診断市場は、2023年に7億3,370万米ドルとなりました。

同市場は、2023年から2033年にかけて14.53%のCAGRで拡大し、2033年には28億4,970万米ドルに達すると予測されています。アジア太平洋のコンパニオン診断市場は、コンパニオン診断ツールの承認の増加、生物医学的イメージングの改善、がん罹患率の上昇の結果として成長しています。これらは、アジア太平洋の個別化がん治療において精密医療とコンパニオン診断の利用が増加している主な原因です。

主要市場統計
予測期間 2023年～2033年
2023年の評価 7億3,370万米ドル
2033年の予測 28億4,970万米ドル
CAGR 14.53%

アジア太平洋におけるコンパニオン診断市場は、個別化治療のニーズの高まりと慢性疾患、特にがんの有病率の上昇により、大きな発展が見込まれています。より専門的で効率的な治療の選択肢を提供するために、コンパニオン診断は、特定の医薬品が最も有効である可能性の高い患者の特定を支援する重要な手段です。コンパニオン診断は、この地域でがんの罹患率が上昇し、精密治療への注目が高まるにつれて、ますます重要性を増しています。

また、アッセイ開発やバイオマーカー探索の技術開発も市場を牽引しています。ゲノム・分子検査技術の進歩により、さまざまな疾患に関連するバイオマーカーが発見され、オーダーメイド治療の開発が容易になっています。さらに、奨励的な法的枠組み、製薬企業による研究開発への資金提供の増加が、市場の拡大に寄与しています。

コンパニオン診断導入の主要企業は中国、インド、日本などで、バイオ医薬品企業と診断薬企業が数多く提携しています。APACコンパニオン診断市場は、患者や医療従事者が個別化医療の利点をより認識するようになるにつれて拡大すると予想され、ヘルスケアエコシステムに関わるすべての関係者に大きな可能性をもたらしています。

当レポートでは、アジア太平洋のコンパニオン診断市場について調査し、市場の概要とともに、技術別、用途別、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

  • 動向：現在および将来の影響評価
  • サプライチェーンの概要
  • 研究開発レビュー
  • 規制状況
  • 歴史的観点から見たコンパニオン診断
  • コンパニオン診断（CDx）開発の構成要素
  • コンパニオン診断（CDx）：将来の可能性
  • 市場力学の概要

第2章 地域

  • 地域別概要
  • 促進要因と抑制要因
  • アジア太平洋

第3章 市場-競合ベンチマーキングと企業プロファイル

  • 今後の見通し
  • 地理的評価
    • Amoy Diagnostics Co., Ltd.
    • Novogene Co, Ltd.
    • Sysmex Corporation

第4章 調査手法

図表

List of Figures

  • Figure 1: Asia-Pacific Companion Diagnostics Market, $Million, 2023, 2026, and 2033
  • Figure 2: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022, 2026, and 2033
  • Figure 3: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022, 2026, and 2033
  • Figure 4: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022, 2026, and 2033
  • Figure 5: Key Industrial Developments in Companion Diagnostics Market, 2023
  • Figure 6: Key Aspects Related to Liquid Biopsy-Based Companion Diagnostics
  • Figure 7: Applications of Digital Diagnostics
  • Figure 8: Supply Chain and Risks within the Supply Chain
  • Figure 9: Companion Diagnostics Market (by Country), January 2021-December 2023
  • Figure 10: Companion Diagnostics (by Year), January 2021-December 2023
  • Figure 11: Evolution of Companion Diagnostics
  • Figure 12: Components Required to Develop Companion Diagnostics
  • Figure 13: Future Prospects of CDx
  • Figure 14: Impact Analysis of Market Navigating Factors, 2023-2033
  • Figure 15: Factors Impacting Reimbursement Scenario
  • Figure 16: Advancements in Companion Diagnostics
  • Figure 17: Future Outlook of Epigenomics
  • Figure 18: Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
  • Figure 19: China Companion Diagnostics Market, $Million, 2022-2033
  • Figure 20: India Companion Diagnostics Market, $Million, 2022-2033
  • Figure 21: Australia Companion Diagnostics Market, $Million, 2022-2033
  • Figure 22: Japan Companion Diagnostics Market, $Million, 2022-2033
  • Figure 23: South Korea Companion Diagnostics Market, $Million, 2022-2033
  • Figure 24: Rest-of-Asia-Pacific Companion Diagnostics Market, $Million, 2022-2033
  • Figure 25: Strategic Initiatives, 2021-2023
  • Figure 26: Share of Strategic Initiatives, 2021-2023
  • Figure 27: Data Triangulation
  • Figure 28: Top-Down and Bottom-Up Approach
  • Figure 29: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Companion Diagnostics Market, Opportunities
  • Table 3: Some of FDA Approved Liquid Biopsy CDx Tests
  • Table 4: Cancer Cases Expected between 2020 and 2040
  • Table 5: Product Approvals in the Field of Companion Diagnostics
  • Table 6: Companion Diagnostics Preparation (by Region), $Million, 2022-2033
  • Table 7: Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 8: Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 9: Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 10: China Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 11: China Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 12: China Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 13: India Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 14: India Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 15: India Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 16: Australia Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 17: Australia Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 18: Australia Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 19: Japan Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 20: Japan Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 21: Japan Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 22: South Korea Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 23: South Korea Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 24: South Korea Companion Diagnostics Market (by Technology), $Million, 2022-2033
  • Table 25: Rest-of-Asia-Pacific Companion Diagnostics Market (by Application), $Million, 2022-2033
  • Table 26: Rest-of-Asia-Pacific Companion Diagnostics Market (by End User), $Million, 2022-2033
  • Table 27: Rest-of-Asia-Pacific Companion Diagnostics Market (by Technology), $Million, 2022-2033
目次
Product Code: BHP2385SS

Introduction to Asia-Pacific Companion Diagnostics Market

The Asia-Pacific companion diagnostics market was valued at $733.7 million in 2023 and is expected to reach $2,849.7 million by 2033, growing at a CAGR of 14.53% between 2023 and 2033. The Asia-Pacific (APAC) companion diagnostics market is growing as a result of increased approvals for companion diagnostic tools, improvements in biomedical imaging, and the rising incidence of cancer. These are the main causes of the increasing use of precision medicine and companion diagnostics in APAC's individualized cancer treatment.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$733.7 Million
2033 Forecast$2,849.7 Million
CAGR14.53%

The market for companion diagnostics in Asia-Pacific (APAC) is expected to develop significantly due to the increased need for personalized therapy and the rising prevalence of chronic diseases, especially cancer. In order to provide more specialized and efficient treatment options, companion diagnostics are crucial instruments that assist in identifying patients who are most likely to benefit from particular medicines. Companion diagnostics are becoming more and more important as the region sees an increase in cancer incidence and a greater focus on precision treatment.

The market is also being driven ahead by technological developments in assay development and biomarker discovery. The development of customized treatments is made easier by the discovery of biomarkers linked to a variety of diseases thanks to advancements in genomic and molecular testing technology. Furthermore, encouraging legal frameworks, more funding for research and development by pharmaceutical companies are contributing to the market's expansion.

Leading the way in the adoption of companion diagnostics are nations like China, India, and Japan, where biopharmaceutical businesses and diagnostic companies have partnered in large numbers. The APAC companion diagnostic market is expected to increase as patients and healthcare professionals become more aware of the advantages of personalized medicine, providing substantial potential for all parties involved in the healthcare ecosystem.

Market Segmentation

Segmentation 1: by Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Next-Generation Sequencing (NGS)
  • Others

Segmentation 2: by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Stomach Cancer
  • Melanoma
  • Others

Segmentation 3: by End User

  • Pharmaceutical and Biotechnology Companies
  • Reference Laboratories and Hospitals
  • Others

Segmentation 4: by Country

  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific companion diagnostics market has been segmented based on various categories, such as technology, application, end user, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Asia-Pacific companion diagnostics market is a highly fragmented market, with many smaller and private companies constantly entering the market. Key players in the Asia-Pacific companion diagnostics market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Amoy Diagnostics Co., Ltd.
  • Novogene Co, Ltd.
  • Sysmex Corporation

Table of Contents

Executive Summary

Scope and Definition

1 Markets

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Companion Diagnostics Market Trend Analysis
    • 1.1.2 Implementation of Liquid Biopsy-Based Companion Diagnostics
    • 1.1.3 Combining Artificial Intelligence and Companion Diagnostics
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
  • 1.3 Research and Development Review
    • 1.3.1 Patent Filing Trend (by Country, Year)
  • 1.4 Regulatory Landscape
    • 1.4.1 Legal Requirements and Framework by the FDA
    • 1.4.2 Legal Requirements and Framework by the MHLW
  • 1.5 CDx from a Historical Perspective
  • 1.6 Constituents for Companion Diagnostics (CDx) Development
  • 1.7 Companion Diagnostics (CDx): Future Potential
  • 1.8 Market Dynamics Overview
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Prevalence of Cancer Cases
      • 1.8.1.2 Increasing Product Approvals in the Field of Companion Diagnostics
      • 1.8.1.3 Advancing Biomedical Imaging as the Driving Force for Precision Medicine's Companion Diagnostics
    • 1.8.2 Market Restraints
      • 1.8.2.1 Uncertain Reimbursement Scenario
      • 1.8.2.2 Stringent Regulatory Approval Processes
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Progress in Companion Diagnostics Driven by Continuous Development and Technological Advancements
      • 1.8.3.2 Introduction of Epigenomics-Based Companion Diagnostics

2 Regions

  • 2.1 Regional Summary
  • 2.2 Drivers and Restraints
  • 2.3 Asia-Pacific
    • 2.3.1 Regional Overview
    • 2.3.2 Driving Factors for Market Growth
    • 2.3.3 Factors Challenging the Market
    • 2.3.4 Application
    • 2.3.5 Product
    • 2.3.6 China
    • 2.3.7 Application
    • 2.3.8 Product
    • 2.3.9 India
    • 2.3.10 Application
    • 2.3.11 Product
    • 2.3.12 Australia
    • 2.3.13 Application
    • 2.3.14 Product
    • 2.3.15 Japan
    • 2.3.16 Application
    • 2.3.17 Product
    • 2.3.18 South Korea
    • 2.3.19 Application
    • 2.3.20 Product
    • 2.3.21 Rest-of-Asia-Pacific
    • 2.3.22 Application
    • 2.3.23 Product

3 Markets - Competitive Benchmarking & Company Profiles

  • 3.1 Next Frontiers.....
  • 3.2 Geographic Assessment
    • 3.2.1 Amoy Diagnostics Co., Ltd.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products/Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Novogene Co, Ltd.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products/Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Sysmex Corporation
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products/Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast